after....
The Company has completed the Recapitalisation Proposal and raised $2,004,000, after payment of $400,000 to the Administrator. These funds allow the Company to continue the development and in time, the commercialisation of its proprietary technologies and products used in the refractive surgery of the human eye. The Company proposes to raise sufficient working capital to carry out its activities and adopt a strategy of using external expertise and intellectual capital to further the development of the Company’s technology via the Joint Venture in an attempt to increase the value of its assets. Q-Vis retains Intellectual Property that will form the basis of a 49:51 Joint Venture with Dr Paul Van Saarloos and Mr Simon Gordon. The aims of the Joint Venture will be to initially evaluate the entire Q-Vis Intellectual Property portfolio to determine which parts of the portfolio should be maintained for future development and possible commercialisation. The Joint Venture will use its initial funding to purchase key items of Q-Vis plant, equipment and stock from the Administrator and pay for necessary regulatory filings to maintain that part of the patent portfolio considered to be of value to the Joint Venture. Any residual funding available will be used towards the further development of Intellectual Property identified as part of the initial evaluation and to pursue opportunities for the exploitation of that Intellectual Property.
